TD Asset Management Inc Sells 11,348 Shares of Apogee Therapeutics Inc. $APGE

TD Asset Management Inc decreased its holdings in Apogee Therapeutics Inc. (NASDAQ:APGE) by 12.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 83,240 shares of the company’s stock after selling 11,348 shares during the period. TD Asset Management Inc’s holdings in Apogee Therapeutics were worth $3,307,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after buying an additional 694 shares during the period. Millennium Management LLC lifted its position in shares of Apogee Therapeutics by 100.0% during the first quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after acquiring an additional 130,164 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after acquiring an additional 383 shares during the period. Fox Run Management L.L.C. bought a new position in shares of Apogee Therapeutics in the second quarter worth $437,000. Finally, Lisanti Capital Growth LLC purchased a new position in shares of Apogee Therapeutics in the second quarter valued at $800,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $72.31 on Thursday. Apogee Therapeutics Inc. has a 52-week low of $26.20 and a 52-week high of $84.56. The company has a fifty day moving average of $72.61 and a 200-day moving average of $60.34. The company has a market capitalization of $5.02 billion, a P/E ratio of -17.14 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.02. As a group, analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Apogee Therapeutics news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total value of $133,525,000.00. Following the completion of the sale, the director owned 298,647 shares of the company’s stock, valued at $22,786,766.10. This represents a 85.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the transaction, the chief executive officer directly owned 1,172,987 shares in the company, valued at $74,308,726.45. This trade represents a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,834,200 shares of company stock worth $139,739,253 in the last quarter. 42.77% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on APGE. Jefferies Financial Group reissued a “buy” rating and set a $95.00 price objective on shares of Apogee Therapeutics in a report on Monday, February 2nd. Stephens initiated coverage on Apogee Therapeutics in a research report on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price target on the stock. Wedbush raised their price objective on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday. Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Sunday, January 25th. Finally, UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.92.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.